SAN MATEO, Calif., April 11, 2023 /PRNewswire/ -- Virtuoso Therapeutics, Inc., a private oncology-focused company developing novel bispecific antibodies today announced that it will present three posters highlighting the preclinical data from leading bispecific antibody and ADC programs at the American Associate for Cancer Research (AACR) 2023 Annual Meeting.
The details of the Company's presentations at the AACR are as follows:
Poster Presentation #1870:
Title: VBI–003, a CD47xEpCAM bispecific antibody as a potential treatment for colorectal and small cell lung cancers
Session Category: Immunology
Session Title: Therapeutic Antibodies 1
Presenting Author: Oi Kwan Wong, Ph.D., Senior Director, Translational Biology
Date/Time: April 17th 9:00AM-12:30PM
Location: Section 25
Poster Presentation #6334:
Title: VBI-002, a CD47xICAM-1 bispecific antibody for the treatment of hepatocellular carcinoma, melanoma and non-small cell lung cancers
Session Category: Immunology
Session Title: Anticancer Immunotherapeutics
Presenting Author: Oi Kwan Wong, Ph.D., Senior Director, Translational Biology
Date/Time: April 19th 9:00AM-12:30PM
Location: Section 22
Poster Presentation #6298:
Title: A novel topoisomerase I inhibitor based anti-ICAM–1 antibody drug conjugate for the treatment of hematologic malignancies and solid tumors
Session Category: Experimental and Molecular Therapeutics
Session Title: Growth Factor Receptors as Therapeutic Targets
Presenting Author: Oi Kwan Wong, Ph.D., Senior Director, Translational Biology
Date/Time: April 19th 9:00AM-12:30PM
Location: Section 21
"We believe that our best-in-class CD47 bispecific antibodies confer greater tumor selectivity without sacrificing potency and efficacy. They have been optimized and are ready to begin IND enabling studies," said Sofie Qiao, PhD, President and CEO of Virtuoso Therapeutics. Posters will be available at www.virtuosotherapuetics.com after the meeting.
About Virtuoso Therapeutics, Inc.
Virtuoso Therapeutics is an oncology-focused company developing novel bispecific antibodies. The team's expertise and insights could address some of the fundamental challenges of these modalities, such as efficacy and therapeutic window. By applying Virtuoso's technology and know-how, the bispecific programs are highly differentiated and have the potential to achieve a unique product profile.
For more information, please visit www.virtuosotherapeutics.com.
Contact Information
Sofie Qiao, Ph.D.
President and CEO
info@virtuosotherapeutics.com
650.666.2753
SOURCE Virtuoso Therapeutics
